Rachel SummersOzempic face — the gaunt, hollow, aged facial appearance that can accompany rapid weight loss from GLP-1 agonist medications like semaglutide — has become one of the most discussed cosmetic side effects of the weight loss drug revolution. Here’s what’s actually happening, why it occurs, and what you can do about it.
What Is Ozempic Face?
“Ozempic face” is an informal term coined by dermatologists and plastic surgeons to describe facial changes that accompany rapid, significant weight loss from GLP-1 agonist medications (Ozempic, Wegovy, Mounjaro, Zepbound). These changes typically include:
- Loss of facial fat, creating a gaunt or hollow appearance
- Deepening of nasolabial folds (lines from nose to corners of mouth)
- Visible bone structure where fat previously softened features
- Sagging or loose skin where facial fat volume has reduced
- Under-eye hollowing and increased visibility of tear troughs
- Overall aged appearance, even in younger patients
Why Does Ozempic Cause Facial Ageing?
Fat Loss Is Not Location-Specific
When we lose weight — through any method — we cannot choose where the fat comes from. The face contains several fat pads (the buccal fat pad, malar fat pad, temporal fat pad, and periorbital fat) that contribute significantly to youthful facial structure. Rapid or significant total body weight loss inevitably depletes these fat compartments alongside fat elsewhere in the body.
Facial Fat as a Structural Scaffold
In youth, facial fat pads provide volume and lift to overlying skin. As we age, these fat compartments naturally shrink and descend — producing the hollow, drooping appearance of an ageing face. Rapid weight loss mimics and accelerates this natural ageing process. The faster and more significant the weight loss, the more pronounced the facial ageing effect.
Skin Elasticity Doesn’t Catch Up
Skin has limited elasticity — its ability to contract and “snap back” after significant volume loss diminishes with age. In someone over 40, the skin’s collagen and elastin network often cannot fully contract after substantial facial fat loss, leaving loose or sagging skin where volume previously provided lift.
How Much Weight Loss Causes Ozempic Face?
There’s no universal threshold — facial fat changes depend on starting weight, rate of loss, age, genetics, and total weight lost. However, facial changes are typically noticed after losses of 10% or more of body weight, and become more pronounced above 15–20% total body weight loss. The rate matters as much as the total amount — slower weight loss gives skin more time to adapt.
Can You Prevent Ozempic Face?
- Lose weight more slowly — a slower rate of loss gives skin more time to adapt. Adjusting medication dose to slow weight loss rate can help
- Strength training — building and maintaining muscle provides underlying structure; resistance training during weight loss on GLP-1 medications is strongly recommended
- Adequate protein intake — GLP-1 medications significantly suppress appetite; ensuring adequate protein (1.2–1.5g per kg body weight) helps preserve muscle and supports skin structure
- Collagen supplementation — some evidence supports collagen peptides for skin elasticity; 10–15g daily may provide modest support
- Stay hydrated — skin appearance is significantly affected by hydration status
How to Fix Ozempic Face
If facial ageing has already occurred, cosmetic medicine offers several options:
- Dermal fillers — hyaluronic acid fillers can restore lost facial volume directly; common areas are the cheeks, temples, tear troughs, and nasolabial folds
- Biostimulators — Sculptra (poly-L-lactic acid) and Radiesse (calcium hydroxylapatite) stimulate collagen production and provide longer-lasting volume restoration
- Skin tightening treatments — radiofrequency, ultrasound (Ultherapy), or microneedling with RF can stimulate collagen remodelling and improve skin laxity
- Surgical options — facelift or mini-lift may be appropriate for significant skin laxity in older patients
Frequently Asked Questions
Ozempic face is the gaunt, hollow, or aged facial appearance that occurs when GLP-1 medications (Ozempic, Wegovy, Mounjaro) cause significant or rapid weight loss. The face loses its fat pad volume — the same process as facial ageing — creating hollowing, sagging, deepened folds, and an overall aged appearance even in younger patients.
Dermal fillers (hyaluronic acid) can restore lost facial volume immediately. Biostimulators like Sculptra stimulate collagen production for longer-lasting results. Prevention is more effective than treatment — slower weight loss, strength training, adequate protein intake, and collagen supplementation can reduce the severity of facial changes during weight loss.
Not everyone who loses weight on GLP-1 medications experiences significant facial ageing. Risk is higher with: older age (less skin elasticity), faster rate of weight loss, greater total weight lost (particularly 15%+ of body weight), and genetic predisposition to facial fat distribution in the face. Those losing weight more slowly or carrying less facial fat to begin with may see minimal facial change.
If you regain the weight, some facial volume may return — but the timing and extent depends on skin elasticity, age, and rate of weight regain. Facial fat loss that has occurred due to weight loss does not automatically reverse simply by stopping the medication. Volume restoration through fillers or biostimulators provides more reliable correction.
This article is for informational purposes only. Discuss the risks and management of facial changes with your prescribing physician and a qualified cosmetic dermatologist or plastic surgeon.
Dr. Maya Chen
Elena Voss
Dr. Rachel Stone
